Funding Rounds
AAVantgarde Bio

AAVantgarde Bio Series A (2023, $65M)

AAVantgarde Bio

Gene therapies for inherited retinal disorders.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series A

Raised Amount: $65.19M

Raised Date: 2023-06-01

Investors